Precision medicine aims to individualise therapeutic interventions, based on OMICS data such as genomics, proteomics, metabolomics etc’, profiling together with histopathological insights to the type, stage, and the grade of the disease, as well as on the potential response of a particular patient to a particular treatment regimen. With next generation sequencing technologies, it is now possible to identify all germline variants of an individual at an affordable cost and thus paving the way for clinicians to provide healthcare from an individual perspective. However, the data that correlate specific disease type, response to specific treatment, and adverse effects as a result of the treatment, are slow to come. There are also critical voices warning us of getting lost in Big Data and advocating a stronger role of physiological models and phenotypic data in drug R&D. Another dimension of this debate is related to the way many companies manage their precision medicine processes and strategies for developing a more agile approach in the field.
The summit on “Controversies in Precision Medicine: where do we stand in drug development”, under the leadership of Professor Dan Peer, Director of Tel Aviv University Cancer Biology Research Center and Translational Medicine, will explore these debates and facilitate discussions on future ways to increase the productivity of biopharmaceutical and clinical innovation.
The event design includes engaging debates, panels and roundtable discussions to foster interaction between participants and stimulate them to search for solutions to the real challenges and opportunities in the industry that will enable change.